Citations

Clear

22 citation(s) found for "Kang, Peter".

Model-based analysis of the relationship between pembrolizumab (MK-3475) exposure and efficacy in patients with advanced or metastatic melanoma.
Gangadhar, Tara C., Hamid, Omid , Dummer, Reinhard , Mehnert, Janice M. , Celentano, Kellie Ann, Lindia, Jill A., Chatterjee, Manash , Turner, David C. , Mayawala, Kapil , Elassaiss‐Schaap, Jeroen , Alwis, Dinesh P. de, Li, Xiaoyun , Ebbinghaus, Scot, Kang, Soonmo Peter, Kefford, Richard , Joseph, Richard W. , Puzanov, Igor , Robert, Caroline , Ribas, Antoni , Daud, Adil

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3068-3068

10.1200/jco.2015.33.15_suppl.3068 Get It

Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001.
Hamid, Omid , Kefford, Richard , Hwu, Wen‐Jen , Gangadhar, Tara C., Dronca, Roxana , Patnaik, Amita , Zarour, Hassane M. , Li, Xiaoyun , Xue, Dahai, Ebbinghaus, Scot, Kang, Soonmo Peter, Perrone, Andrea , Hodi, F. Stephen , Wolchok, Jedd D. , Ribas, Antoni , Robert, Caroline , Weber, Jeffrey S. , Joshua, Anthony M. , Daud, Adil , Joseph, Richard W. , Perrone, Andrea Marie

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 3000-3000

10.1200/jco.2015.33.15_suppl.3000 Get It

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
Hodi, F. Stephen , Hamid, Omid , Hwu, Wen-Jen, Gangadhar, Tara C., Patnaik, Amita , Dronca, Roxana , Zarour, Hassane M. , Gergich, Kevin, Li, Xiaoyun , Iannone, Robert, Kang, Soonmo Peter, Ebbinghaus, Scot, Ribas, Antoni , Kefford, Richard , Daud, Adil , Wolchok, Jedd D. , Hwu, Wen‐Jen , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S. , Robert, Caroline

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: LBA9000-LBA9000

10.1200/jco.2014.32.15_suppl.lba9000 Get It

Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Kefford, Richard , Hamid, Omid , Hodi, F. Stephen , Gangadhar, Tara C., Dronca, Roxana , Patnaik, Amita , Zarour, Hassane M. , Dolled‐Filhart, Marisa, Lunceford, Jared , Emancipator, Kenneth , Ebbinghaus, Scot, Kang, Soonmo Peter, Hwu, Wen‐Jen , Ribas, Antoni , Robert, Caroline , Daud, Adil , Wolchok, Jedd D. , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3005-3005

10.1200/jco.2014.32.15_suppl.3005 Get It

Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475.
Elassaiss‐Schaap, Jeroen , Hodi, F. Stephen , Hamid, Omid , Hwu, Wen‐Jen , Kefford, Richard , Patnaik, Amita , Alwis, Dinesh P. de, Perrone, Andrea , Kang, Soonmo Peter, Ebbinghaus, Scot, Anderson, Keaven M. , Gangadhar, Tara C., Joseph, Richard W. , Wolchok, Jedd D. , Joshua, Anthony M. , Ribas, Antoni , Robert, Caroline , Daud, Adil , Hersey, Peter , Weber, Jeffrey S. , Perrone, Andrea Marie

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3015-3015

10.1200/jco.2014.32.15_suppl.3015 Get It

Evaluation of immune-related response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.
Hodi, F. Stephen , Hamid, Omid , Kefford, Richard , Hwu, Wen‐Jen , Gangadhar, Tara C., Dronca, Roxana , Perrone, Andrea , Gammage, Linda, Hille, Darcy A., Xue, Dahai, Kang, Soonmo Peter, Chun, Patrick, Ebbinghaus, Scot, Ribas, Antoni , Daud, Adil , Robert, Caroline , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S. , Perrone, Andrea Marie, Wolchok, Jedd D.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3006-3006

10.1200/jco.2014.32.15_suppl.3006 Get It

Randomized comparison of two doses of the anti-PD-1 monoclonal antibody MK-3475 for ipilimumab-refractory (IPI-R) and IPI-naive (IPI-N) melanoma (MEL).
Hamid, Omid , Hodi, F. Stephen , Kefford, Richard , Hwu, Wen‐Jen , Gangadhar, Tara C., Patnaik, Amita , Gergich, Kevin, Li, Xiaoyun , Chun, Patrick, Ebbinghaus, Scot, Kang, Soonmo Peter, Robert, Caroline , Ribas, Antoni , Wolchok, Jedd D. , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S. , Joseph, Richard W. , Daud, Adil

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3000-3000

10.1200/jco.2014.32.15_suppl.3000 Get It

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
Joseph, Richard W. , Elassaiss‐Schaap, Jeroen , Kefford, Richard , Hwu, Wen-Jen , Joshua, Anthony M. , Ribas, Antoni , Hodi, F. Stephen , Hamid, Omid , Robert, Caroline , Daud, Adil , Dronca, Roxana , Hersey, Peter , Weber, Jeffrey S. , Patnaik, Amita , Alwis, Dinesh P. de, Perrone, Andrea , Zhang, Jin , Kang, Soonmo Peter, Ebbinghaus, Scot, Anderson, Keaven M. , Gangadhar, Tara C., Daud, Adil I , Hwu, Wen‐Jen , Wolchok, Jedd D. , Weber, Jeffrey

Mayo Clinic

Clinical Cancer Research | April 23, 2018 | Volume: 24 | Issue: 20 | Pages: 4960-4967

10.1158/1078-0432.ccr-17-2386 | PMID 29685882 Get It

Abstract Purpose: The purpose of this study was to assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in pembrolizumab-treated patients with advanced melanoma in KEYNOTE-001 (NCT01295827). Experimental Design: BTS was quantified by adding the sum of the longest dimensions of all measurable baseline target lesions. BTS as a dichotomous and continuous variable was evaluated with other baseline factors using logistic regression for objective response rate (ORR) and Cox regression for overall survival (OS). Nominal P values with no multiplicity adjustment describe the strength of observed associations. Results: Per central review by RECIST v1.1, 583 of 655 patients had baseline measurable disease and were included in this post hoc analysis. Median BTS was 10.2 cm (range, 1–89.5). Larger median BTS was associated with Eastern Cooperative Oncology Group performance status 1, elevated lactate dehydrogenase (LDH), stage M1c disease, and liver metastases (with or without any other sites; all P ≤ 0.001). In univariate analyses, BTS below the median was associated with higher ORR (44% vs. 23%; P < 0.001) and improved OS (HR, 0.38; P < 0.001). In multivariate analyses, BTS below the median remained an independent prognostic marker of OS (P < 0.001) but not ORR. In 459 patients with available tumor programmed death ligand 1 (PD-L1) expression, BTS below the median and PD-L1–positive tumors were independently associated with higher ORR and longer OS. Conclusions: BTS is associated with many other baseline clinical factors but is also independently prognostic of survival in pembrolizumab-treated patients with advanced melanoma. Clin Cancer Res; 24(20); 4960–7. ©2018 AACR. See related commentary by Warner and Postow, p. 4915
Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
Hodi, F. Stephen , Kefford, Richard , Hamid, Omid , Hwu, Wen‐Jen , Gangadhar, Tara C., Patnaik, Amita , Dronca, Roxana , Zarour, Hassane M. , Gergich, Kevin, Li, Xiaoyun , Iannone, Robert, Kang, Soonmo Peter, Ebbinghaus, Scot, Ribas, Antoni , Daud, Adil , Wolchok, Jedd D. , Joshua, Anthony M. , Hersey, Peter , Weber, Jeffrey S. , Robert, Caroline

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 32 | Issue: 18_suppl | Pages: LBA9000-LBA9000

10.1200/jco.2014.32.18_suppl.lba9000 Get It

LBA9000^ Background: The humanized monoclonal IgG4 anti-PD-1 antibody MK-3475 has demonstrated durable antitumor activity in MEL and NSCLC. We evaluated MK-3475 efficacy and safety in a pooled analysis of 411 MEL pts. Methods: A nonrandomized cohort of ipilimumab-naive (IPI-N) and IPI-treated (IPI-T) pts treated with MK-3475 10 mg/kg Q2W, 10 mg/kg Q3W, or 2 mg/kg Q3W and randomized cohorts of IPI-N and IPI-T pts treated with 2 Q3W or 10 Q3W were included. Response was assessed every 12 wk by RECIST 1.1 by independent central review and by immune-related response criteria (irRC) by investigator. Results: 162 pts were treated at 2 Q3W, 192 at 10 Q3W, and 57 at 10 Q2W. 190 pts were IPI-N and 221 were IPI-T. As of the 10/18/2013 cutoff, all pts had ≥6 mo follow-up and >75% had ≥9 mo follow-up. Among the 365 pts with measurable disease at baseline, ORR by RECIST was 40% (95% CI 32%-48%) in IPI-N and 28% (95% CI 22%-35%) in IPI-T pts. Responses were durable (88% ongoing at analysis). Median PFS by RECIST was 24 wk in IPI-N and 23 wk in IPI-T pts. Median OS was not reached, with 1-y OS of 71% in all pts. Benefit was observed by both RECIST and irRC at all doses and schedules in IPI-N and IPI-T pts (Table). MK-3475 demonstrated activity in all major subgroups irrespective of ECOG PS, LDH levels, BRAFmutation, M stage, and number and type of prior therapy. Overall, 12% of pts experienced drug-related grade 3/4 AEs and 4% discontinued due to a drug-related AE. There were no drug-related deaths. Conclusions: MK-3475 showed durable responses and a manageable safety profile across dose and schedules in IPI-N and IPI-T MEL pts. The observed efficacy and safety suggest MK-3475 may be an appropriate treatment for all pts with MEL. Clinical trial information: NCT01295827. [Table: see text]